Table 2.
Clinical development of mAbs against antigens other than CD20.
| Antibody | Target | Characteristics | Phase of development |
|---|---|---|---|
| Epratuzumab | CD22 | Humanized anti-CD22 mAb | Phase II in NHL |
| Inotuzumab ozogamicin | CD22 | Humanized anti-CD22 mAb conjugated with calicheamicin | Phase I/II in NHL |
| 90Y-epratuzumab tetraxetan | CD22 | Humanized anti-CD22 mAb conjugated with90Y | Phase I/II in NHL |
| Brentuximab vedotin | CD30 | Chimeric anti-CD30 mAb conjugated with vedotin | Phase II in HL |
| Lucatumumab | CD40 | Fully human anti-CD40 mAb | Phase I/II in NHL and HL |
| Alemtuzumab | CD52 | Humanized anti-CD52 mAb | FDA approved for resistant CLL, phase III as first-line in CLL, phase II in DLBCL |
| Blinatumomab | CD19/CD3 | Anti-CD19/anti-CD3 BiTE (bispecific T-cell engager) | Phase I in NHL |